ArticleFrontiers in public health2023
Carbapenem resistant
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 10 citations in OpenAlex.
- Antimicrobial Resistance Trends in Carbapenem-Resistant Enterobacterales in a Saudi Healthcare Setting.Microorganisms · 2026Article
- Carbapenem resistance in community-acquired urinary tract infections caused byJAC-antimicrobial resistance · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Current progress in antibacterial agents for carbapenem-resistant enterobacterales.Frontiers in pharmacology · 2026Review
- Feasibility Study on Risk Stratification for Multidrug-Resistant Organism Infections Among ICU Patients in the United Arab Emirates.Risk management and healthcare policy · 2026Article
- Whole-genome sequencing-based characterization of resistome and virulome inFrontiers in microbiology · 2026Article
- Article
- Genomic characterization of two distinct Klebsiella pneumoniae strains in a fatal case of relapsed acute myelogenous leukemia: a case report.BMC infectious diseases · 2025Article
- First national study on genomic profiling ofEnvironmental challenges (Amsterdam, Netherlands) · 2025Article
- Detection and Genomic Characteristics of NDM-19- and QnrS11-Producing O101:H5Microorganisms · 2025Article
- Article
- Impact of an antimicrobial time-out program on antimicrobial consumption rate in hospitalized patients: a quasi-experimental study on the national antimicrobial stewardship program in Iran : Iranian antimicrobial stewardship program.Journal of pharmaceutical health care and sciences · 2025Article
- Prevalence of carbapenem-resistantSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
Corrections and comments
- Comment on
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: In this study, we retrospectively describe CRE isolated from 317 surveillance sites, including 87 hospitals and 230 centers/clinics from 2010 to 2021. The associated clinical, demographic, and microbiological characteristics are presented by relying on the UAE national AMR surveillance program. Data was analyzed using WHONET microbiology laboratory database software (http://www.whonet.org). Results: A total of 14,593 carbapenem resistant Conclusion: This study supports the need to monitor CRE in the UAE and draws attention to the significant increase of ertapenem resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.